Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Buy" by Brokerages

Shares of Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) have earned an average rating of "Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $15.00.

Several research analysts recently issued reports on NKTX shares. HC Wainwright lowered their target price on Nkarta from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, November 11th. RODMAN&RENSHAW upgraded Nkarta to a "strong-buy" rating in a research report on Wednesday, October 9th. Mizuho reduced their target price on Nkarta from $20.00 to $16.00 and set an "outperform" rating on the stock in a report on Thursday, November 21st. Needham & Company LLC lowered their price target on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating for the company in a report on Friday, November 8th. Finally, Rodman & Renshaw started coverage on shares of Nkarta in a research note on Wednesday, October 9th. They issued a "buy" rating and a $14.00 price objective on the stock.

Institutional Investors Weigh In On Nkarta

A number of large investors have recently bought and sold shares of NKTX. Vanguard Group Inc. boosted its position in shares of Nkarta by 26.0% during the 1st quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company's stock worth $21,255,000 after purchasing an additional 405,753 shares in the last quarter. Wasatch Advisors LP raised its stake in Nkarta by 31.7% during the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company's stock worth $8,293,000 after buying an additional 442,125 shares during the period. Geode Capital Management LLC grew its position in Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company's stock valued at $5,294,000 after purchasing an additional 33,927 shares during the period. State Street Corp boosted its position in shares of Nkarta by 1.4% during the third quarter. State Street Corp now owns 1,098,062 shares of the company's stock valued at $4,963,000 after buying an additional 15,569 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Nkarta by 12.0% in the second quarter. Renaissance Technologies LLC now owns 912,872 shares of the company's stock worth $5,395,000 after purchasing an additional 98,000 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Stock Up 14.6 %

NASDAQ NKTX traded up $0.38 on Thursday, hitting $2.99. The company's stock had a trading volume of 1,848,032 shares, compared to its average volume of 1,155,259. The firm has a market cap of $211.00 million, a PE ratio of -1.59 and a beta of 0.86. The company's 50-day moving average is $3.63 and its 200 day moving average is $5.17. Nkarta has a 1-year low of $2.38 and a 1-year high of $16.24.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.